Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Verge Genomics

Verge Genomics
2015 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series A1 LATEST DEAL TYPE
21 INVESTORS
Description

Developer of a drug discovery platform designed to reduce the time and cost of drug discovery. The company's platform utilizes machine learning to develop new therapeutics and is specifically designed for neurological diseases, and can analyze thousands of datasets to identify new targets, predict effective drugs and stratify patient subpopulations, enabling healthcare providers to improve patient outcomes as well as fundamentally bend the cost curve of pharmaceutical development.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • Two Tower Place
  • Suite 950
  • San Francisco, CA 94080
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Verge Genomics’s full profile, request a free trial.

Verge Genomics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A1) 25-Jan-2019 000.00 Completed Generating Revenue
3. Early Stage VC (Series A) 16-Jul-2018 0000 000.00 0000 Completed Generating Revenue
2. Seed Round 28-Oct-2015 $4M $4.12M Completed Startup
1. Accelerator/Incubator 18-Aug-2015 $120K $120K 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Verge Genomics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A6 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A5 000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A4 00,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A3 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.00
Series A2 1,698,104 $0.001000 6% $2.65 $2.65 1x $2.65 8.37%
Series A1 8,502,149 $0.001000 6% $3.31 $3.31 1x $3.31 34.94%
To view this company’s complete Cap Table, request access »

Verge Genomics Competitors (37)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Relay Therapeutics Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00 000000000000 Venture Capital-Backed Guilford, CT 00 0000 00000000000 0000
00000000 000000000 Venture Capital-Backed Cambridge, MA 00 000.00 0000000000 0 000.00
0000000 Venture Capital-Backed Framingham, MA 0 0000 0000000000 0 0000
00000000 Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
To view this company’s complete list of competitors, request access »

Verge Genomics Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
ALS Investment Fund Venture Capital Minority 000 0000 000000 0
Basis Set Ventures Venture Capital Minority 000 0000 000000 0
Lifeforce Capital Venture Capital Minority 000 0000 000000 0
OS Fund Venture Capital Minority 000 0000 000000 0
Threshold Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 21 investors. Get the full list »

Verge Genomics Executive Team (7)

Name Title Board
Seat
Contact
Info
Alice Zhang Ph.D Co-Founder, Chief Executive Officer & Board Member
C. Anthony Altar Ph.D Senior Scientific Fellow & Advisor
Michelle Mighdoll Strategic Initiatives & Data Acquisition Executive
Jason Chen MD Co-Founder & Advisor
Ben Jackson JD Vice President of Operations and Finance

1 Former Executive

You’re viewing 5 of 7 executives. Get the full list »

Verge Genomics Board Members (4)

Name Representing Role Since Contact
Info
Alice Zhang Ph.D Verge Genomics Co-Founder, Chief Executive Officer & Board Member 000 0000
Dave Madge WuXi AppTec Board Member 000 0000
Emily Melton Verge Genomics Board Member 000 0000
Melanie Leitner Ph.D ALS Investment Fund Board Member 000 0000